Ann: June Quarterly Activity and Cashflow Report, page-16

The deal is not dead otherwise management would have to disclose it to the market. I do think $89k in cash receipts for the quarter is pretty bad when staff costs are $330k. The company doesn't make enough from the derma division for that to be the only revenue coming in. I'm highly interested in knowing when the pharma revenue is going to be recognized.

6c is a good price at the moment imo.

- GMP certified facility
- Second crop harvest due in September
- Malta facility planned
- CannEpil sales to commence soon
- Value for current IP

I can justify current market cap on those facts but it would be hard to argue a higher price without more revenue or a time frame on expected revenue.